Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Christie, where are we going with lipoprotein(a) [Lp(a)]? Have we reached the end of the road, or is there something on the horizon? Christie M. Ballantyne, MD, FACC: We’re just moving, and I agree with my colleagues. I screen everybody in my personal practice. I also do cascade …